AER-271

SKU: orb1941024

Description

AER-271 (AER271) is a selective, small molecule inhibitor of aquaporin-4 (AQP4), the prodrug of AER-270 with enhanced solubility; shows improved neurological outcome and reduced swelling in two models of CNS injury complicated by cerebral edema.Other Indication Phase 1 Clinical(In Vivo):AER-271 is converted in vivo to AER-270 by endogenous phosphatases. AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest.AER-271 reduces cerebral edema and improves neurological outcomes in rodent ischemic stroke models. Mice treated with AER-271 (5 mg/kg; i.p. injection) show improved outcomes and reduced cerebral edema in a model of ischemic stroke.

Key Properties

• CAS Number: 634913-39-6
• MW: 463.653
• Purity: >98% (HPLC)
• Formula: C₁₅H₉ClF₆NO₅P
• SMILES: O=P(O)(OC1=CC=C(Cl)C=C1C(NC2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)=O)O
• Target: Other Targets
• Solubility: In Vitro: DMSO : 125 mg/mL (269.60 mM)

Bioactivity

• In Vivo:
  Animal model: Male mice (C57BL/6J, 8-12 week-old, 25-30 g). Dosage: 5 mg/kg. Administration: Treated by i.p. injection. Result: Had better outcomes with an average neurological score of 0.89±0.31 compared with control mice receiving vehicle had an average neurological score of 2.50±0.62.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

AER271

Quick Database Links

Gene Symbol

Other Targets